ClinVar Miner

Submissions for variant NM_003036.4(SKI):c.878G>A (p.Gly293Asp)

gnomAD frequency: 0.00003  dbSNP: rs756571135
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001064110 SCV001228986 uncertain significance Shprintzen-Goldberg syndrome 2019-02-05 criteria provided, single submitter clinical testing This variant has not been reported in the literature in individuals with SKI-related conditions. This variant is present in population databases (rs756571135, ExAC 0.01%). This sequence change replaces glycine with aspartic acid at codon 293 of the SKI protein (p.Gly293Asp). The glycine residue is moderately conserved and there is a moderate physicochemical difference between glycine and aspartic acid. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV001760036 SCV001989604 uncertain significance not provided 2019-07-16 criteria provided, single submitter clinical testing In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge
Ambry Genetics RCV004030522 SCV004950895 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2023-10-30 criteria provided, single submitter clinical testing The c.878G>A (p.G293D) alteration is located in exon 1 (coding exon 1) of the SKI gene. This alteration results from a G to A substitution at nucleotide position 878, causing the glycine (G) at amino acid position 293 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.